De Facto Communications is one of Europe's most successful public relations consultancies in the fields of life science, healthcare, medical education and clinical trials. In partnership with our clients, we approach our work with a passion and commitment that delivers award-winning, integrated communications programmes based on effective strategy, original thinking and attention-grabbing creativity.
Headquartered in London, De Facto Communications operates internationally to reach our clients' target audiences, wherever they might be. De Facto is part of the Bell Pottinger Group, the UK's No. 1 public relations consultancy, No 1 'opinion leading' research group and the country's fastest growing marketing services group
| Contact Details: |
| 330 High Holborn |
| London |
| |
| WC1V 7QD |
| United Kingdom |
| Tel: | 020 7861 3838 |
| Fax: | 020 7861 3839 |
| Email: | info@defacto.com |
| WWW: | http://www.defacto.com
|
|
Loading...
|
Press Releases on De Facto Communications:
|
 |
| SynCo Bio Partners Wins Best Contract Manufacturing Organization 2009 ViE Award |
30th April, 2009 |
|
AMSTERDAM, April 30 /PRNewswire/ -- SynCo Bio Partners B.V. (Amsterdam, The Netherlands), the cGMP
manufacturer of clinical and commercial biopharmaceuticals, has won the
Vaccine Industry Excellence
|
| Epistem Announces Research and Development Collaboration With a Major Pharmaceutical Company |
2nd March, 2009 |
|
MANCHESTER, England, March 2 /PRNewswire/ -- Epistem Plc (LSE:EHP) the UK biotechnology and research
services company announced today that they have signed a research and
development collaboration
|
| AMT Amsterdam Molecular Therapeutics (AMT) Obtains Orphan Drug
|
1st March, 2004 |
Amt |
AMT Amsterdam Molecular Therapeutics (AMT) Obtains Orphan Drug Designation for its LPL Gene Therapy Product
Amsterdam, 17 March 2004. AMT today announced that its adeno-associated viral vector
|
| DXS And Sangtec Molecular Diagnostics Announce Licensing Agreement Of
|
1st February, 2004 |
Dxs |
DXS
And Sangtec Molecular Diagnostics Announce Licensing Agreement Of Scorpions[Tm]
Technology
18th February 2004 Manchester (UK) and Stockholm (Sweden):
DxS Ltd, a genotyping services and
|
| EXONHIT THERAPEUTICS announces EURO 8.3 MILLION in fund to support
|
1st February, 2004 |
Exonhit |
EXONHIT THERAPEUTICS
announces EURO 8.3 MILLION in
fund to support clinical development
2 February 2004 Paris,
France...ExonHit Therapeutics, the alternative RNA
|
Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 239 times since April 2007, the link to the organisation's website has been followed 32 times
Search for more companies in London
Search for more companies in
This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for
De Facto Communications
